Pharmacokinetics of cytisine, an α4 β2 nicotinic receptor partial agonist, in healthy smokers following a single dose.

Cytisine, an α4 β2 nicotinic receptor partial agonist, is a plant alkaloid that is commercially extracted for use as a smoking cessation medication. Despite its long history of use, there is very little understanding of the pharmacokinetics of cytisine. To date, no previous studies have reported cytisine concentrations in humans following its use as a smoking cessation agent. A high performance liquid chromatography-ultraviolet (HPLC-UV) method was developed and validated for analysis of Tabex® and nicotine-free oral strips, two commercial products containing cytisine. A sensitive liquid chromatography-mass spectrometry (LC-MS) method was developed and validated for the quantification of cytisine in human plasma and for the detection of cytisine in urine. Single-dose pharmacokinetics of cytisine was studied in healthy smokers. Subjects received a single 3 mg oral dose administration of cytisine. Cytisine was detected in all plasma samples collected after administration, including 15 min post-dose and at 24 h. Cytisine was renally excreted and detected as an unchanged drug. No metabolites were detected in plasma or urine collected in the study. No adverse reactions were reported.

[1]  M. Stevenson,et al.  What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. , 2014, Health technology assessment.

[2]  J. Samet.  Cytisine is effective for smoking cessation: should clinicians use it? , 2014, Evidence-Based Medicine.

[3]  A. Chan,et al.  Simultaneous detection of 22 toxic plant alkaloids (aconitum alkaloids, solanaceous tropane alkaloids, sophora alkaloids, strychnos alkaloids and colchicine) in human urine and herbal samples using liquid chromatography-tandem mass spectrometry. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  J. Prochaska,et al.  Cytisine, the world’s oldest smoking cessation aid , 2013, BMJ.

[5]  R. West,et al.  Cytisine and the failure to market and regulate for human health , 2013, Thorax.

[6]  H. McRobbie,et al.  Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis , 2013, Thorax.

[7]  J. Duan,et al.  Comparative analysis of quinolizidine alkaloids from different parts of Sophora alopecuroides seeds by UPLC-MS/MS. , 2012, Journal of pharmaceutical and biomedical analysis.

[8]  R. West,et al.  Placebo-controlled trial of cytisine for smoking cessation. , 2011, The New England journal of medicine.

[9]  D. Bertrand,et al.  Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence , 2010, British journal of pharmacology.

[10]  D. Svinarov,et al.  Pharmacokinetics of cytisine after single intravenous and oral administration in rabbits , 2010, Interdisciplinary toxicology.

[11]  T. Tensfeldt,et al.  Population pharmacokinetic analysis of varenicline in adult smokers. , 2009, British journal of clinical pharmacology.

[12]  Prabhat Jha,et al.  Avoidable global cancer deaths and total deaths from smoking , 2009, Nature Reviews Cancer.

[13]  R. Papke,et al.  Cytisine-Based Nicotinic Partial Agonists as Novel Antidepressant Compounds , 2009, Journal of Pharmacology and Experimental Therapeutics.

[14]  P. Ravva,et al.  Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2009, Clinical therapeutics.

[15]  P. Tutka.  Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation , 2008, Expert opinion on investigational drugs.

[16]  T. Henle,et al.  Simultaneous determination of thirteen plant alkaloids in a human specimen by SPE and HPLC. , 2008, Journal of separation science.

[17]  D. Vinnikov,et al.  A Double-blind, Randomised, Placebo-controlled Trial of Cytisine for Smoking Cessation in Medium-dependent Workers , 2008 .

[18]  B. Feng,et al.  Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study , 2008, Clinical pharmacology and therapeutics.

[19]  F. Peters,et al.  Detection and validated quantification of toxic alkaloids in human blood plasma--comparison of LC-APCI-MS with LC-ESI-MS/MS. , 2007, Journal of mass spectrometry : JMS.

[20]  R. West,et al.  An uncontrolled trial of cytisine (Tabex) for smoking cessation , 2006, Tobacco Control.

[21]  T. Fullerton,et al.  Pharmacokinetics, Safety, and Tolerability After Single and Multiple Oral Doses of Varenicline in Elderly Smokers , 2006, Journal of clinical pharmacology.

[22]  W. Zatónski,et al.  Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. , 2006, Pharmacological reports : PR.

[23]  A. Burstein,et al.  Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers , 2006, Journal of clinical pharmacology.

[24]  Jason Gong,et al.  Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial , 2006 .

[25]  David Gonzales,et al.  Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial , 2006 .

[26]  R. Obach,et al.  METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRO , 2006, Drug Metabolism and Disposition.

[27]  J. Leon,et al.  A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors , 2005, Schizophrenia Research.

[28]  Dao-feng Chen,et al.  Determination of quinolizidine alkaloids in Sophora tonkinensis by HPCE. , 2005, Phytochemical analysis : PCA.

[29]  Josue P. Keely,et al.  Shape of the relapse curve and long-term abstinence among untreated smokers. , 2004, Addiction.

[30]  Nicholas P. Jewell,et al.  Characterization of the receptor mediating the nicotine discriminative stimulus , 2004, Psychopharmacology.

[31]  V. Boido,et al.  Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities. , 2003, Farmaco.

[32]  M. Jann,et al.  Correlation of Cytochrome P450 (CYP) 1A2 Activity Using Caffeine Phenotyping and Olanzapine Disposition in Healthy Volunteers , 2003, Neuropsychopharmacology.

[33]  D. Greenblatt,et al.  CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[34]  Richard Doll,et al.  Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies , 2000, BMJ : British Medical Journal.

[35]  Karthik Venkatakrishnan,et al.  Nortriptyline E‐10‐Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme‐Inducing Drugs , 1999, Journal of clinical pharmacology.

[36]  D. Schrenk,et al.  A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers , 1998, European Journal of Clinical Pharmacology.

[37]  C. Alm,et al.  Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. , 1994, British journal of clinical pharmacology.

[38]  L. Kozlowski,et al.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. , 1991, British journal of addiction.

[39]  B. Tang,et al.  Caffeine as a metabolic probe: Exploration of the enzyme‐inducing effect of cigarette smoking , 1991, Clinical pharmacology and therapeutics.

[40]  B. Testa,et al.  Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline , 1990, Neuropharmacology.

[41]  G. Damm,et al.  Pharmacokinetic studies with 3H-cytisine. , 1980, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.